Rapamycin and inulin for booster vaccine response stimulation (RIVASTIM)—rapamycin: study protocol for a randomised, controlled trial of immunosuppression modification with rapamycin to improve SARS-CoV-2 vaccine response in kidney transplant recipients
Abstract Kidney transplant recipients are at an increased risk of severe COVID-19-associated hospitalisation and death. Vaccination has been a key public health strategy to reduce disease severity and infectivity, but the effectiveness of COVID vaccines is markedly reduced in kidney transplant recip...
Main Authors: | Matthew Tunbridge, Griffith B. Perkins, Julian Singer, Tania Salehi, Tracey Ying, Branka Grubor-Bauk, Simon Barry, Beatrice Sim, Pravin Hissaria, Steven J. Chadban, P. Toby Coates |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2022-09-01
|
Series: | Trials |
Subjects: | |
Online Access: | https://doi.org/10.1186/s13063-022-06634-w |
Similar Items
-
Rapamycin and inulin for third-dose vaccine response stimulation (RIVASTIM): Inulin – study protocol for a pilot, multicentre, randomised, double-blinded, controlled trial of dietary inulin to improve SARS-CoV-2 vaccine response in kidney transplant recipients
by: Julian Singer, et al.
Published: (2022-12-01) -
Progress in the Treatment of Topical Rapamycin Preparations
by: WANG Senfen, et al.
Published: (2023-04-01) -
Toxicidade pulmonar induzida pela rapamicina Lung toxicity induced by rapamycin
by: C Damas, et al.
Published: (2006-11-01) -
Rapamycin: Drug Repurposing in SARS-CoV-2 Infection
by: Jiri Patocka, et al.
Published: (2021-03-01) -
Does Lymphovenous Anastomosis Effect Mammalian Target of Rapamycin Inhibitor-associated Lymphedema Patients?
by: Inah Yoon, et al.